McKesson (NYSE:MCK – Get Rating) is scheduled to be releasing its earnings data after the market closes on Wednesday, February 1st. Analysts expect McKesson to post earnings of $6.34 per share for the quarter. McKesson has set its FY 2023 guidance at $24.45-$24.95 EPS and its FY23 guidance at $24.45-24.95 EPS.Parties interested in registering for the company’s conference call can do so using this link.
McKesson (NYSE:MCK – Get Rating) last announced its quarterly earnings results on Tuesday, November 1st. The company reported $6.06 EPS for the quarter, missing the consensus estimate of $6.13 by ($0.07). The company had revenue of $70.16 billion during the quarter, compared to analyst estimates of $69.66 billion. McKesson had a net margin of 0.76% and a negative return on equity of 267.09%. On average, analysts expect McKesson to post $25 EPS for the current fiscal year and $26 EPS for the next fiscal year.
McKesson Stock Up 0.4 %
NYSE:MCK opened at $376.50 on Wednesday. The firm has a market cap of $53.39 billion, a PE ratio of 26.57, a price-to-earnings-growth ratio of 1.51 and a beta of 0.63. McKesson has a 12 month low of $238.59 and a 12 month high of $401.78. The company’s 50-day moving average price is $377.89 and its two-hundred day moving average price is $363.81.
Insider Buying and Selling at McKesson
Institutional Investors Weigh In On McKesson
A number of large investors have recently made changes to their positions in MCK. GABELLI & Co INVESTMENT ADVISERS INC. bought a new position in McKesson during the 1st quarter valued at approximately $306,000. Zions Bancorporation N.A. raised its stake in shares of McKesson by 286.8% in the first quarter. Zions Bancorporation N.A. now owns 847 shares of the company’s stock worth $259,000 after buying an additional 628 shares during the period. Private Advisory Group LLC purchased a new position in McKesson during the first quarter valued at approximately $235,000. Penserra Capital Management LLC lifted its stake in shares of McKesson by 7.9% during the 1st quarter. Penserra Capital Management LLC now owns 747 shares of the company’s stock valued at $228,000 after buying an additional 55 shares in the last quarter. Finally, Geneos Wealth Management Inc. lifted its position in shares of McKesson by 16.6% in the first quarter. Geneos Wealth Management Inc. now owns 716 shares of the company’s stock valued at $219,000 after acquiring an additional 102 shares in the last quarter. 85.23% of the stock is currently owned by institutional investors.
Wall Street Analysts Forecast Growth
A number of brokerages have issued reports on MCK. Barclays lifted their target price on shares of McKesson from $375.00 to $415.00 and gave the stock an “equal weight” rating in a report on Wednesday, November 2nd. Cowen boosted their target price on shares of McKesson from $384.00 to $416.00 in a report on Wednesday, November 2nd. Morgan Stanley upped their price objective on McKesson from $403.00 to $420.00 and gave the company an “overweight” rating in a research note on Friday, January 6th. StockNews.com began coverage on shares of McKesson in a research note on Wednesday, October 12th. They set a “strong-buy” rating for the company. Finally, Mizuho boosted their price target on McKesson from $345.00 to $376.00 and gave the company a “neutral” rating in a research note on Monday, November 14th. Two research analysts have rated the stock with a hold rating, seven have given a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $411.20.
McKesson Corporation provides healthcare services in the United States and internationally. It operates through four segments: U.S. Pharmaceutical, International, Medical-Surgical Solutions, and Prescription Technology Solutions (RxTS). The U.S. Pharmaceutical segment distributes branded, generic, specialty, biosimilar, and over-the-counter pharmaceutical drugs and other healthcare-related products.
- Get a free copy of the StockNews.com research report on McKesson (MCK)
- EVgo Stock is Charged Up to Ride the EV Adoption Wave
- Qualcomm Gets a Boost from Analysts, but is it Time to Buy?
- High-Yield, Deep-Value Verizon Puts In A Bottom
- Should You Bet Against The Nasdaq 100 With This Inverse ETF?
- Can Coty Stock Emerge in 2023 With Upside
Receive News & Ratings for McKesson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for McKesson and related companies with MarketBeat.com's FREE daily email newsletter.